Melanoma

Skin cancer death rates in UK men have more than tripled since the early 1970s, according to new analysis released today by Cancer Research UK.

The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer.

Over the last 10 years, melanoma skin cancer among men in the UK has increased by almost 50%.

Researchers have uncovered a new link between higher levels of testosterone in the blood and increased risk of melanoma skin cancer in men.

Ultraviolet radiation can cause a rare type of eye cancer, conjunctival melanoma.

Cancer Research UK scientists have developed a new way to analyse blood for evidence of cancer that could be up to ten times more sensitive than previous methods.

An immunotherapy and a targeted cancer drug were among the latest batch of NHS approvals from the Scottish Medicines Consortium (SMC). 

Researchers have demonstrated an approach which, used in parallel with existing treatments, wipes out the ‘survival system’ of cancer cells.

Vitamin D influences the behaviour of melanoma cells in the lab by making them less aggressive, Cancer Research UK scientists have found.

Melanoma skin cancer incidence rates have soared by 45% since 2004, according to the latest figures released by Cancer Research UK.